Tag: europe

SEOUL, South Korea, July 29, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that it will release its 2025 second quarter financial results after the market closes on Tuesday, August 12, 2025, and host a conference call and simultaneous webcast at 5:00 p.m. ET (2:00 p.m. PT) that day. Both the call and webcast are open to the general public. On the call, DoubleDown management will review the Company’s financial results and provide a business update, followed by a question-and-answer session.

MUNICH, July 29, 2025 (GLOBE NEWSWIRE) -- Meliodays Medical and Celanese Corporation (NYSE: CE) have signed an agreement related to Meliodays’ pre-clinical development of MelioOne^®, the first hormone-free non-contraceptive intrauterine device (IUD) designed to deliver localized relief for menstrual pain. MelioOne^® combines the proven VitalDose^® Drug Delivery Platform from Celanese with Meliodays’ innovative IUD design and non-hormonal active pharmaceutical ingredient (API).

The Europe defibrillator market, valued at USD 3.87 billion in 2024, is projected to reach USD 7.23 billion by 2033, with a CAGR of 7.2%. Growth drivers include rising cardiovascular diseases, technological advancements, and government initiatives to expand public defibrillator access. Key segments include implantable and external defibrillators with significant usage in hospitals, public, and home settings. The market faces challenges such as high device costs and regulatory complexities. Leading players like Medtronic and Philips are instrumental in market expansion through innovations and strategic partnerships across Europe.

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

Atari enters into an agreement to invest in Thunderful Group AB

Stellantis Reports First Half 2025 Results Reflecting External Headwinds and Ongoing Recovery Actions; Financial Guidance Re-Established

Progress on share buyback programme